首页> 美国卫生研究院文献>other >MK-1775 a potent Wee1 inhibitor synergizes with gemcitabine to achieve tumor regressions selectively in p53-deficient pancreatic cancer xenografts

【2h】

MK-1775 a potent Wee1 inhibitor synergizes with gemcitabine to achieve tumor regressions selectively in p53-deficient pancreatic cancer xenografts

机译：MK-1775有效的WEE1抑制剂用吉西他滨协同增长以实现肿瘤回归在P53缺乏胰腺癌异种移植物中选择性地实现肿瘤回归

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeInvestigate the efficacy and pharmacodynamic effects of MK-1775, a potent Wee1 inhibitor, in both monotherapy and in combination with gemcitabine using a panel of p53-deficient and p53-wild type human pancreatic cancer xenografts.

著录项

期刊名称 other
作者
N.V. Rajeshkumar; Elizabeth De Oliveira; Niki Ottenhof; James Watters; David Brooks; Tim Demuth; Stuart D. Shumway; Shinji Mizuarai; Hiroshi Hirai; Anirban Maitra; Manuel Hidalgo;
展开▼
作者单位

展开▼
年(卷),期 -1(17),9
年度 -1
页码 2799–2806
总页数 15
原文格式 PDF
正文语种
中图分类
关键词
MK-1775 Wee1 kinase pancreatic cancer chemotherapy cell cycle inhibitor;

机译：MK-1775;Wee1激酶;胰腺癌;化学疗法;细胞周期抑制剂;

相似文献

外文文献
专利

1. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. [J] . Rajeshkumar NV, De Oliveira E, Ottenhof N, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第9期

机译：MK-1775是一种有效的Wee1抑制剂，可与吉西他滨协同作用，选择性地在p53缺乏的胰腺癌异种移植物中实现肿瘤消退。
2. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. [J] . Hirai H, Iwasawa Y, Okada M, Molecular cancer therapeutics . 2009,第11期

机译：MK-1775对Wee1激酶的小分子抑制选择性地使p53缺陷的肿瘤细胞对DNA损伤剂敏感。
3. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway [J] . WangY., ZhouY., JiaG., Biochemical Pharmacology . 2014,第3期

机译：紫草素在胰腺癌异种移植模型中抑制肿瘤生长并与吉西他滨协同作用：涉及NF-κB信号通路
4. A theranostic gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells [C] . Qiao Jin, Haijie Han, Haibo Wang, World biomaterials congress . 2016

机译：具有基于AIE的细胞内点亮特性的治疗性吉西他滨前药，可选择性抑制胰腺癌细胞
5. Optimization of the time course of stromal modulation and minimization of drug-drug interactions in a multiple tyrosine kinase inhibitor/gemcitabine combination in pancreatic cancer [D] . Trueman, Sheryl A. 2017

机译：胰腺癌中多种酪氨酸激酶抑制剂/吉西他滨组合的基质调节时间过程的优化和药物-药物相互作用的最小化
6. Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas [O] . Jenny M. Kreahling, Parastou Foroutan, Damon Reed, -1

机译：WEE1抑制作用mK-1775导致人类肉瘤肿瘤抑制和增强疗效的吉西他滨
7. MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts [O] . N.V. Rajeshkumar, Elizabeth De Oliveira, Niki Ottenhof, 2011

机译：MK-1775，有效的WEE1抑制剂，用吉西他滨协同增长，以实现肿瘤回归，在P53缺乏胰腺癌异种移植物中选择性地实现肿瘤回归

MK-1775 a potent Wee1 inhibitor synergizes with gemcitabine to achieve tumor regressions selectively in p53-deficient pancreatic cancer xenografts

摘要

著录项

相似文献

相关主题

期刊订阅